Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT1001 for MIS-C
NCT05022303Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of larazotide in multisystem inflammatory syndrome (MIS), sponsored by Massachusetts General Hospital. Started Oct 2021; status: terminated.
02
Drugs
larazotide
03
Conditions
multisystem inflammatory syndrome (MIS)
Beyond the preview
Go deeper on NCT05022303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022303.